### I Amendment

**S2000**, A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Symptomatic Brain Metastases  (Version Date 03/19/24)

### II Continuing Review

**S2104**, Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors  (Version Date 08/18/23)

### III Continuing Review

**S2212**, Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study  (Version Date 06/20/23)

### IV Continuing Review

**A031801**, A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCaL)  (Version Date 02/15/22)

### V Continuing Review

**A052101**, A Randomized Phase 3 Trial of Continuous vs Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)  (Version Date 11/21/23)
VI  Continuing Review

EA1183,  FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE  (Version Date 10/21/22)

VII  Continuing Review

EA2183,  A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)  (Version Date 03/28/24)

VIII  Continuing Review

NRG-BR004,  A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer  (Version Date 08/15/22)

IX  Continuing Review

NRG-GI008,  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)  (Version Date 09/25/23)